美国FDA已授予Tamibarotene(以前称为SY-1425)快速通道资格,用于治疗高危骨髓增生异常综合征(HR-MDS)。Tamibarotene是一种口服一流的选择性视黄酸受体α(RARα)激动剂,目前正在评估与阿扎胞苷联合治疗新诊断的RARA基因过表达的HR-MDS患者。 根据之前的研究结果,大约30%的HR-MDS患者呈RARA阳性。在之前的研究结果中,...
研究性组合Tamibarotene加阿扎胞苷 (Vidaza) 和维奈托克 (Venclexta) 可能比单独使用标准治疗 (SOC) 阿扎胞苷和维奈托克更耐受,从而解决了不适合的单核细胞急性髓性白血病 (AML) 患者未满足的需求根据医学博士 Brian Ball 的说法,用于强化化疗。 此前,2 期 SY-1425-201 试验 (NCT02807558) 评估了选择性视黄酸...
2024年8月12日,Syros公司宣布处于2期阶段RARα激动剂SY-1425/Tamibarotene用于治疗新诊断RAR基因过表达的AML,因SELECT-AML-1中期分析结果疗效不具优效性而停止招募。 对前40名随机患者接受约三个月的研究药物或停止治疗后,进行预先指定的非约束性无效性分析。三联组(SY-1425+维奈克拉+阿扎胞苷)与双联组(维奈克拉...
We found that RARA-high cell lines sensitive to SY-1425 (THP-1, OCI-AML3, MV4-11, and EOL-1) tend to be most similar to monocytes, while RARA-low cell lines insensitive to SY-1425 (KG-1a, Kasumi-1, and OCI-M1) are more HSPC or erythroid-like.We then studied the effect of ...
Previously, the phase 2 SY-1425-201 trial (NCT02807558) evaluated the efficacy and safety of tamibarotene, a selective retinoic acid receptor alpha (RARA) inhibitor, plus azacitidine in patients with newly diagnosed AML who were unfit for intensive chemotherapy. In this trial, the patients with...
8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid;4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid;Am 80;Am 80 (RAR agonist);Am 80 (pharmaceutical);Amnolake;INNO 507;NSC 608000;OP 01;RR 110;Retinoid AM 80;SY 1425;TM 441;TOS 80T;Tamibaro...
carbonyl]benzoic Acid; AM 80; Am 80 (pharmaceutical); Am 80 (RAR agonist); AM80; Amnolake; Benzoic acid, 4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]-; INNO 507; NSC 608000; OP 01; Retinoid AM 80; RR 110; SY 1425; Tamibarotene; TM 441; TOS...
研究性组合Tamibarotene加阿扎胞苷 (Vidaza) 和维奈托克 (Venclexta) 可能比单独使用标准治疗 (SOC) 阿扎胞苷和维奈托克更耐受,从而解决了不适合的单核细胞急性髓性白血病 (AML) 患者未满足的需求根据医学博士 Brian Ball 的说法,用于强化化疗。 此前,2 期 SY-1425-201 试验 (NCT02807558) 评估了选择性视黄酸...
1032PPharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patientsIsocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to alpha ketoglutarate. IDH occurs in three isoforms, IDH1, ...
tamibaroteneSY-1425RARAretinoidACUTE MYELOID-LEUKEMIATRANS-RETINOIC ACIDVENETOCLAXRESISTANCETHERAPYTamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately,...